Literature DB >> 22263437

Prevalence of Fusobacterium necrophorum in persistent sore throat samples.

S L Price1, S Hardy, P Gale, G P Basten.   

Abstract

Entities:  

Mesh:

Year:  2011        PMID: 22263437     DOI: 10.1080/09674845.2011.11978256

Source DB:  PubMed          Journal:  Br J Biomed Sci        ISSN: 0967-4845            Impact factor:   3.829


× No keyword cloud information.
  5 in total

1.  Unusual neurological presentation of Fusobacterium necrophorum disease.

Authors:  Nasrean Haddad; Trefor Morris; Rishi Dhillon; Frances Gibbon
Journal:  BMJ Case Rep       Date:  2016-01-12

2.  Antibody development to Fusobacterium necrophorum in patients with peritonsillar abscess.

Authors:  T E Klug; J-J Henriksen; M Rusan; K Fuursted; K A Krogfelt; T Ovesen; C Struve
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-05-09       Impact factor: 3.267

Review 3.  A systematic review of Fusobacterium necrophorum-positive acute tonsillitis: prevalence, methods of detection, patient characteristics, and the usefulness of the Centor score.

Authors:  T E Klug; M Rusan; K Fuursted; T Ovesen; A W Jorgensen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-08-27       Impact factor: 3.267

4.  A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2013 recommendations by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM)(a).

Authors:  Ellen Jo Baron; J Michael Miller; Melvin P Weinstein; Sandra S Richter; Peter H Gilligan; Richard B Thomson; Paul Bourbeau; Karen C Carroll; Sue C Kehl; W Michael Dunne; Barbara Robinson-Dunn; Joseph D Schwartzman; Kimberle C Chapin; James W Snyder; Betty A Forbes; Robin Patel; Jon E Rosenblatt; Bobbi S Pritt
Journal:  Clin Infect Dis       Date:  2013-07-10       Impact factor: 9.079

5.  Acute sore throat and Fusobacterium necrophorum in primary healthcare: a systematic review and meta-analysis.

Authors:  Stefan Malmberg; Susanna Petrén; Ronny Gunnarsson; Katarina Hedin; Pär-Daniel Sundvall
Journal:  BMJ Open       Date:  2021-06-04       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.